Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $0.05, $0.54 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $56.37 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Reading (RDI) Tops Q2 EPS by 4c
• Mosaic sets pricing for tender offers on up to $1.4B in debt